Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exenokine-21
- Development stage
- Phase 1
- Lead developer
- Junshi Biosciences
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Exenokine-21 is a recombinant fusion protein comprising interleukin-21 (IL-21) fused to an anti-human serum albumin (HSA) single-domain nanobody. It is designed as a half-life extended IL-21 agonist for cancer immunotherapy. Exenokine-21 acts as an IL-21 receptor agonist and has demonstrated superior antitumor activity compared to unmodified IL-21 in preclinical models. The drug enhances immune responses by activating pathways associated with CD8+ T cell and NK cell cytotoxicity and can potentiate the efficacy of immune checkpoint inhibitors such as PD1 and TIGIT blockades. It is being developed primarily for use in combination with standard-of-care therapies for various cancers including lymphoma, head and neck cancer, renal cell carcinoma (RCC), melanoma, solid tumors, and liver cancer[1][2][3][4].
- Other names
- exenokine 21exenokine21exenokine-21JS014JS-014JS 014AWT-008AWT008AWT 008
02
Targets
IL21R (Interleukin-21 receptor)
Beyond the preview
Go deeper on exenokine-21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exenokine-21.